priavoid.com
  • Home
  • About us
    • Overview
    • Strategy
    • Management
    • Supervisory Board
    • Scientific Advisory Board
    • Careers
    • History
  • Drug Development
    • Therapeutic Focus
    • Technology
    • Pipeline
  • Investors and Media
    • News
    • Events
    • Partnering
    • Archive
  • Contact us
Select Page

Dr. Dagmar Juergens attended the annual AAIC online conference

AAIC 2021

Dr. Dagmar Juergens attended the annual
AAIC online conference

More information

News & Events:

Team Assistant (m/w/d)
Team Assistant (m/w/d)

January 28, 2022

Staff Scientist Cellular Assays 
Staff Scientist Cellular Assays 

January 28, 2022

Staff Scientist in vitro ADME
Staff Scientist in vitro ADME

January 28, 2022

TIDES Boston May, 2022
TIDES Boston May, 2022

December 14, 2021

Funding from The Michael J. Fox Foundation
Funding from The Michael J. Fox Foundation

February 24, 2021

Priavoid closes financing round
Priavoid closes financing round

February 12, 2021

Sprunginnovationsprojekt geht neue Wege in der Alzheimer-Therapie
Sprunginnovationsprojekt geht neue Wege in der Alzheimer-Therapie

February 11, 2021

Alzheimer´s Research: Important Milestone for PRI-002
Alzheimer´s Research: Important Milestone for PRI-002

February 4, 2021

Nobel Prize winner Stanley Prusiner joins Priavoid’s supervisory board
Nobel Prize winner Stanley Prusiner joins Priavoid’s supervisory board

December 9, 2020

New CEO of Priavoid
New CEO of Priavoid

September 2, 2020

Priavoid Headquarters at LSC Düsseldorf
Priavoid Headquarters at LSC Düsseldorf

March 6, 2020

Seed Investment
Seed Investment

May 6, 2019

Prof. Willbold´s interview with PharmaVentures
Prof. Willbold´s interview with PharmaVentures

January 23, 2018

Clinical trial with PRI-002
Clinical trial with PRI-002

May 31, 2017

  • Home
  • Investors and Media
  • Legal Notice
  • Privacy Policy
  • Contact us
Copyright © 2021 Priavoid GmbH
×

Study Coordinator

Die PRInnovation GmbH, ein Tochterunternehmen der SPRIND, arbeitet an der klinischen Weiterentwicklung eines Medikamentenkandidaten mit innovativem Wirkmechanismus gegen die Alzheimer-Demenz. Hierbei kooperieren wir eng mit der Firma Priavoid.

Wir suchen Sie zum nächstmöglichen Zeitpunkt zur Unterstützung des PRInnovation Teams, um den Proof-of-Concept in einer klinischen Phase II Studie zu demonstrieren.

Jetzt bewerben